Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

1.46
Delayed Data
As of 4:00pm ET
 +0.03 / +2.10%
Today’s Change
1.16
Today|||52-Week Range
8.95
-82.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$387.9M

Company Description

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Contact Information

Novavax, Inc.
20 Firstfield Road
Gaithersburg Maryland 20878
P:(240) 268-2000
Investor Relations:

Employees

Shareholders

Individual stakeholders7.35%
Mutual fund holders51.29%
Other institutional11.83%

Top Executives

Stanley C. ErckPresident, Chief Executive Officer & Director
Robert DariusSenior Vice President-Quality Operations
Barclay A. PhillipsChief Financial Officer, Treasurer & Senior VP
Gregory M. GlennPresident-Research & Development
John A. HerrmannSecretary, Senior Vice President & General Counsel